Absci Corporation (ABSI)

Over the past six months, Absci's stock has seen a positive change of approximately 21.69% to 24.34%. As of January 9, 2026, the stock price was $3.34 per share, an increase of 17.02% from January 13, 2025. In December 2025, Absci announced new human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates the stem cell niche, and also announced a partnership with Landon Donovan and the dosing of the first participants in its Phase 1/2a HEADLINE™ Trial for ABS-201™. In November 2025, Absci reported its Q3 2025 earnings, posting an EPS of -$0.20, which met analysts' expectations. In August 2025, Absci held its Second Quarter 2025 Business Update and Financial and Operating Results Conference Call. In May 2025, Absci reported its Q1 2025 financial results, with revenue increasing 33% year-over-year to $1.2 million, initiated a first-in-human study for ABS-101, and reported promising non-human primate data for ABS-201.

Information directly detailing demand seasonality for Absci Corp.'s specific products and services is not explicitly available. Its revenue stream may be more dependent on the timing and success of partnerships, research milestones, and clinical trial progress rather than traditional consumer demand seasonality. However, historical data suggests that buying Absci Corp (ABSI) stock in October has the highest probability of a positive return, while June has the lowest probability.

Absci Corporation is a biotechnology company specializing in drug and target discovery, utilizing a data-first generative AI platform and synthetic biology to accelerate the creation of novel protein therapeutics. The company focuses on AI-driven drug discovery and synthetic biology/biomanufacturing. Absci's core business segments include AI-Driven Drug Discovery and Synthetic Biology and Biomanufacturing. The company's Integrated Drug Creation™ platform aims to accelerate time to clinic and increase the probability of success. Absci's preclinical development programs include ABS-101 for inflammatory bowel disease, ABS-201 for androgenetic alopecia, ABS-301 for immuno-oncology, and ABS-501 for oncology. The company generates revenue through collaborations, partnerships, licensing agreements, and service contracts.

Absci's headquarters are located in Vancouver, Washington, USA. The company also maintains an AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.

Absci's brand reputation in the past year appears to be positively influenced by its advancements in generative AI drug creation and its pipeline progress. Positive human ex vivo data for ABS-201 showing hair growth stimulation and stem cell niche regeneration, a partnership with Landon Donovan, and the initiation of the Phase 1/2a HEADLINE™ Trial for ABS-201 have positively affected Absci's reputation. Collaboration with Oracle Cloud Infrastructure (OCI) and Advanced Micro Devices (AMD) to leverage high-performance computing for its generative AI models and the initiation of the first-in-human study for ABS-101 and promising non-human primate data for ABS-201 have also contributed to the positive reputation.

Absci Corporation's ownership is primarily held by institutional investors and company insiders. Approximately 62.06% to 64.29% of the company's stock is held by institutional shareholders, including Fmr LLC, ARK Investment Management LLC, BlackRock, Inc., Redmile Group LLC, and Vanguard Group Inc. Insiders own about 7.87% to 33.08% of Absci's stock, with Redmile Group LLC being the largest individual shareholder. CEO Sean McClain directly owns approximately 5.86% of the company. Retail investors hold about 2.63% to 30.06% of the remaining float.